by Clinical Neuropsychologist | Friday, August 23, 2024 | Dementia
Abstract INTRODUCTION We used clinical assessment records to provide pan-Canadian estimates of the prevalence and risks associated with recent (within the last 3 days) critical wandering among home care clients, with and without dementia. METHODS The data source is...
by Clinical Neuropsychologist | Thursday, August 22, 2024 | Dementia
Abstract INTRODUCTION We examined the associations of polygenic risk score (PRS) with Alzheimer’s disease (AD) and plasma biomarkers in the Chinese population. METHODS This population-based study used baseline data from MIND-China (2018; n = 4873) and follow-up...
by Clinical Neuropsychologist | Thursday, August 22, 2024 | Dementia
Abstract INTRODUCTION Reduced brain energy metabolism, mammalian target of rapamycin (mTOR) dysregulation, and extracellular amyloid beta (Aβ) oligomer (xcAβO) buildup are some well-known Alzheimer’s disease (AD) features; how they promote neurodegeneration is...
by Clinical Neuropsychologist | Wednesday, August 21, 2024 | Dementia
Abstract INTRODUCTION CT1812 is in clinical development for the treatment of Alzheimer’s disease (AD). Cerebrospinal fluid (CSF) exploratory proteomics was employed to identify pharmacodynamic biomarkers of CT1812 in mild to moderate AD from two independent...
by Clinical Neuropsychologist | Wednesday, August 21, 2024 | Dementia
Abstract Neurogenesis persists throughout adulthood in the hippocampus and contributes to specific cognitive functions. In Alzheimer’s disease (AD), the hippocampus is affected by pathology and functional impairment early in the disease. Human AD patients have...
